The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...

Many people who take GLP-1 drugs find that their cravings disappear. I went to a Buddhist monastery to understand why that ...

Dopamine also explains why the use of drugs such as cocaine produces pleasure by blocking the absorption of the neurotransmitter and keeping its levels elevated in the body. Although dopaminergic ...

Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...

NEW YORK -- New York City Mayor Eric Adams pleaded innocent Friday to federal bribery charges, rejecting claims that he accepted overseas travel, campaign cash and other perks from foreign interests ...

Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...

People with schizophrenia will soon have a new treatment option after the FDA approved its first new treatment for the mental ...

A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...

The U.S. FDA has approved Cobenfy, a dual M1/M4 muscarinic agonist that offers a fundamentally different approach to treating schizophrenia. The fixed dose combination of xanomeline-trospium is the ...

The phase 3 Tempo-1 trial for tavapadon, a dopamine receptor partial agonist, demonstrated significant efficacy as a monotherapy in early Parkinson's disease. Patients receiving the drug at doses of 5 ...

Bristol Myers Squibb received U.S. Food and Drug Administration (FDA) approval on Thursday for its groundbreaking ...